Infigratinib is a Reversible Inhibitor and Mechanism-based Inactivator of Cytochrome P450 3A4

2021 ◽  
pp. DMD-AR-2021-000508
Author(s):  
Lloyd Wei Tat Tang ◽  
Jian Wei Teng ◽  
Siew Kwan Koh ◽  
Lei Zhou ◽  
Mei Lin Go ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Reversible Inhibitor ◽  
Cytochrome P450 3A4

scholarly journals Formulation and in-vivo Evaluation of Novel Topical Gel of Lopinavir for Targeting HIV

2019 ◽  
Vol 16 (4) ◽  
pp. 270-279 ◽  
Author(s):  
Huda Ansari ◽  
Prabha Singh
Keyword(s):  
Cytochrome P450 ◽  
Sustained Release ◽  
Skin Permeation ◽  
Oral Suspension ◽  
Poloxamer 407 ◽  
In Vivo Studies ◽  
Reversible Inhibitor ◽  
Cytochrome P450 3A4 ◽  
Topical Gel

Background: Lopinavir is a specific reversible inhibitor of the enzyme HIV protease with mean oral bioavailability of less than 20 % due to extensive hepatic metabolism by cytochrome P450 3A4. The reported half-life of Lopinavir is 5-6 hours and the maximum recommended daily dose is 400 mg/day. All the marketed tablet and capsule formulations of lopinavir are generally combined with Ritonavir, a potent inhibitor of cytochrome P450 3A4, to minimize presystemic metabolism of lopinavir. Hence, to overcome limitations associated with oral administration of lopinavir and to promote single drug administration, utilization of vesicular nanocarriers through topical route could prove to be effective, as the approach combines the inherent advantages of topical route and the drug-carrying potential of vesicular nanocarriers across the tough and otherwise impervious skin barrier layer, i.e., stratum corneum. Objective: The objective was to develop solid lipid nanoparticles (SLN) of lopinavir and formulate a topical gel for improved systemic bioavailability of lopinavir. Method: SLNs were prepared using high-pressure homogenization technique and optimized. The nanoparticles were characterized by SEM to confirm their spherical shape. Differential Scanning Calorimetry (DSC) analysis was carried out to ensure the entrapment of drug inside the SLNs. A comparative evaluation was done between SLN based gel and plain gel of drug by performing exvivo skin permeation studies using Franz diffusion cell. To explore the potential of topical route, invivo bioavailability study was conducted in male Wistar rats. Results: The optimized formulation composed of Compritol 888ATO (0.5 %) as a lipid, Poloxamer 407 (0.25 %) as a surfactant and Labrasol (0.25 %) as a co-surfactant gave the maximum entrapment of 69.78 % with mean particle size of 48.86nm. The plain gel of the drug gave a release of 98.406 ± 0.007 % at the end of 4hours whereas SLN based gel gave a more sustained release of 71.197 ±0.006 % at the end of 12hours ex-vivo. As observed from the results of in-vivo studies, highest Cmax was found with SLN based gel (20.3127 ± 0.6056) µg/ml as compared to plain gel (8.0655 ± 1.6369) µg/ml and oral suspension (4.2550 ± 16.380) µg/ml of the drug. Also, the AUC was higher in the case of SLN based gel indicating good bioavailability as compared to oral suspension and plain gel of drug. Conclusion: Lopinavir SLN based gel was found to have modified drug release pattern providing sustained release as compared to plain drug gel. This indicates that Lopinavir when given topically has a good potential to target the HIV as compared to when given orally.

scholarly journals CO Binding Kinetics of Human Cytochrome P450 3A4

1995 ◽  
Vol 270 (10) ◽  
pp. 5014-5018 ◽  
Author(s):  
Aditya P. Koley ◽  
Jeroen T. M. Buters ◽  
Richard C. Robinson ◽  
Allen Markowitz ◽  
Fred K. Friedman
Keyword(s):  
Cytochrome P450 ◽  
Binding Kinetics ◽  
Cytochrome P450 3A4 ◽  
Human Cytochrome ◽  
Kinetics Of

scholarly journals Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report

2021 ◽  
Vol 22 (12) ◽  
pp. 6480
Author(s):  
Céline K. Stäuble ◽  
Markus L. Lampert ◽  
Thorsten Mikoteit ◽  
Martin Hatzinger ◽  
Kurt E. Hersberger ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Case Report ◽  
Adverse Drug Reactions ◽  
Active Metabolite ◽  
Hepatic Metabolism ◽  
Cytochrome P450 3A4 ◽  
Drug Reactions ◽  
Drug Induced ◽  
Potential Impact ◽  
Intermediate Metabolizer

We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and 400 mg. The extensive hepatic metabolism of quetiapine is mainly attributed to cytochrome P450 3A4 (CYP3A4). However, there is recent evidence supporting the idea of CYP2D6 playing a role in the clearance of the quetiapine active metabolite norquetiapine. Interestingly, both patients we are reporting of are carriers of the CYP2D6*4 variant, predicting an intermediate metabolizer phenotype. Additionally, co-medication with a known CYP2D6 inhibitor and renal impairment might have further affected quetiapine pharmacokinetics. The herein reported cases could spark a discussion on the potential impact of a patient’s pharmacogenetic predisposition in the treatment with quetiapine. However, further studies are warranted to promote the adoption of pharmacogenetic testing for the prevention of drug-induced toxicities associated with quetiapine.

scholarly journals Design of New Schiff-Base Copper(II) Complexes: Synthesis, Crystal Structures, DFT Study, and Binding Potency toward Cytochrome P450 3A4

ACS Omega ◽  
2021 ◽  
Author(s):  
Tunde L. Yusuf ◽  
Segun D. Oladipo ◽  
Sizwe Zamisa ◽  
Hezekiel M. Kumalo ◽  
Isiaka A. Lawal ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Schiff Base ◽  
Crystal Structures ◽  
Dft Study ◽  
Cytochrome P450 3A4

Homotropic cooperativity of monomeric cytochrome P450 3A4 in a nanoscale native bilayer environment

2004 ◽  
Vol 430 (2) ◽  
pp. 218-228 ◽  
Author(s):  
Bradley J. Baas ◽  
Ilia G. Denisov ◽  
Stephen G. Sligar
Keyword(s):  
Cytochrome P450 ◽  
Cytochrome P450 3A4
Sign in / Sign up

Export Citation Format

Share Document